MEDIVIR AB – INTERIM REPORT, JANUARY – JUNE 2017
April - JuneSignificant events during the quarter · Positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma was presented. · Enrolment completed in the MIV-711 osteoarthritis extension study and data monitoring committee recommended to “Go Ahead”. Financial summary · Net turnover for the continuing operations totalled SEK 9.5 million (36.9 m), SEK 7.7 million (24.2 m) of which comprised the second quarter’s royalties for simeprevir. Other operating income totalled SEK 1.9 million (2.7 m). · The loss before interest,